Sentinel Oncology

About:

Sentinel Oncology is a drug discovery company specialising in the delivery of candidate drugs to treat diseases.

Website: http://www.sentineloncology.com/

Top Investors: Wellcome Trust, Innovate UK, Eurostars, University of Cambridge Enterprise, Biomedical Catalyst Fund

Description:

Sentinel Oncology was founded in 2005 in Cambridge, UK and is a drug discovery company dedicated to the development and commercialisation of new therapeutics to treat cancer patients for whom there is currently an unmet medical need. The Sentinel Oncology portfolio includes two programmes progressing towards IND. We are further developing a novel approach, “Targeted Synergy” that is designed to enhance therapeutic index by delivering the effects of drugs directly to the tumour. Sentinel oncology is a fully integrated drug discovery company seeking to develop high quality drug candidates for partnering with the biotechnology and pharmaceutical industry. Our strategy relies on seeking partners and collaborators to maximise the value of our programmes.

Total Funding Amount:

6.3M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2005-01-01

Founders:

Robert Boyle, Stuart Travers

Number of Employees:

1-10

Last Funding Date:

2018-05-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai